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Several barriers separate the central nervous system (CNS) from the rest of the body.
These barriers are essential for regulating the movement of fluid, ions, molecules, and
immune cells into and out of the brain parenchyma. Each CNS barrier is unique and highly
dynamic. Endothelial cells, epithelial cells, pericytes, astrocytes, and other cellular
constituents each have intricate functions that are essential to sustain the brain’s
health. Along with damaging neurons, a traumatic brain injury (TBI) also directly insults
the CNS barrier-forming cells. Disruption to the barriers first occurs by physical damage to
the cells, called the primary injury. Subsequently, during the secondary injury cascade, a
further array of molecular and biochemical changes occurs at the barriers. These changes
are focused on rebuilding and remodeling, as well as movement of immune cells and
waste into and out of the brain. Secondary injury cascades further damage the CNS
barriers. Inflammation is central to healthy remodeling of CNS barriers. However,
inflammation, as a secondary pathology, also plays a role in the chronic disruption of
the barriers’ functions after TBI. The goal of this paper is to review the different barriers
of the brain, including (1) the blood-brain barrier, (2) the blood-cerebrospinal fluid barrier,
(3) the meningeal barrier, (4) the blood-retina barrier, and (5) the brain-lesion border. We
then detail the changes at these barriers due to both primary and secondary injury
following TBI and indicate areas open for future research and discoveries. Finally, we
describe the unique function of the pro-inflammatory cytokine interleukin-1 as a central
actor in the inflammatory regulation of CNS barrier function and dysfunction after a TBI.
Keywords: neuroinflammation, neuroimmunology, glia, neurotrauma, edema, interleukin-1 receptor 1, IL1R1
INTRODUCTION
The central nervous system (CNS) relies on the immune system for proper maintenance, recovery,
and repair functions in health, disease, or following neurotrauma. Yet, the CNS and the vast
majority of the systemic immune system are separated by various barriers (1). The CNS barriers –
often erroneously thought of as solid fortress walls separating the CNS from the body – are highly
dynamic. Extensive cellular and molecular interactions coordinate the ingress and egress of fluid,
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molecules, and cells across the CNS borders. A pivotal point in
the loss of healthy CNS function often occurs when the
coordination of events at the CNS barriers is skewed. There are
many examples of barrier disruption in CNS diseases. There may
be no better example of barrier disruption than neurotrauma.
Each year, an estimated 2 million people in the United States
alone sustain a TBI (2). While these numbers are significant, they
still vastly underestimate the pervasiveness of TBIs. Many
individuals, including victims of intimate partner violence, fail
to report their injuries, while others may not need or seek
emergency medical treatment (2, 3). The damage caused to the
brain, regardless of hospitalization, is real. A TBI, including one
that may be viewed as ‘only a concussion,’ can have lasting
impacts on one’s quality of life.
The physical disruption of the cells within the brain due to the
force of a TBI constitute the primary injury and can affect
neurons, glia and vasculature (4). The primary injury then
starts secondary injury cascades, which can disrupt the brain
and its barriers for months to years after the initial injury (5).
These secondary injury cascades involve many biochemical and
cellular events that seek to restore brain function and worsen the
neural damage caused by the primary injury.
Secondary injury mechanisms are those processes most
amenable to therapeutic intervention. Following injury
anywhere in the body, control of inflammation is one of the
most clinically successful ways to restore function and quality of
life – although the CNS has largely been left out of these
successful treatments. After a TBI, inflammation in the brain is
different from inflammation to peripheral tissues. The CNS
barriers are largely responsible for these differences.
Interleukin-1 (IL-1) is a ‘master cytokine,’ initiating a cascade
of inflammatory pathways. IL-1 exists in two forms IL-1a and
IL-1b. Both IL-1a and IL-1b signal mainly through IL-1
Receptor 1 (IL-1R1) (6). IL-1R1 is uniquely positioned at
critical CNS barrier interfaces (7–9). Further, IL-1 can remain
chronically above normal levels for months to years after TBI
(10, 11). Thus, IL-1/IL-1R1 is likely a critical control hub for
restoring CNS barriers after an injury.
In the current review, we will present the different CNS
barriers and describe how both primary and secondary injury
after TBI changes these barriers. We will then explain how
inflammation, explicitly driven by pro-inflammatory cytokine
interleukin-1 (IL-1), might be a mechanism behind changes to
CNS barriers following TBI. This review will highlight the
essential and dynamic role of CNS barriers in TBI-secondary
injury cascades and describe how, through the modulation of IL-
1, therapies can be developed to help people recover and do so
more quickly after a TBI and return to their preinjury life.
BLOOD BRAIN BARRIER (BBB)
Injection of trypan blue dye into the vasculature, which stained
the vasculature throughout the body, yet left the CNS unmarked,
led to the BBB discovery over a century ago. In the subsequent
100+ years, many illustrative studies have defined the vital and
dynamic nature of the BBB in health and disease. While it is well
known that a TBI disrupts the BBB, there is still much that
remains unexplored, both in terms of the natural history of BBB
disruption as a contributor to TBI-induced dysfunction and as a
viable therapeutic target.
Blood Brain Barrier Overview
The BBB is a highly regulated physiologic barrier between the
CNS and the periphery, with specialized brain endothelial cells
controlling the majority of the barrier functions (Figure 1A).
The brain endothelial cells block the paracellular diffusion of
water-soluble molecules into the brain parenchyma. At the same
time, blood gases, oxygen and carbon dioxide can diffuse
passively across the BBB, as well as many small, lipophilic
molecules (12, 13). However, larger polar molecules and many
essential nutrients, such as glucose and amino acids, cannot
diffuse across the BBB and are blocked from passing through the
paracellular route. Instead, to traverse the BBB, brain endothelial
cells use selective transporters and channels to move more
complex molecules like essential nutrients, ions, and other
polar, hydrophilic molecules across the BBB (12, 13). Specific
methods of transport include solute carriers, ATP-binding
cassette transporters, receptor mediated transcytosis, and
mononuclear cell migration (12).
The tight junctions and adherens junctions exist between
brain endothelial cells to create a tightly-sealed barrier. Tight
junctions are located apically between endothelial cells and are
arranged in strands of interconnected, intramembranous,
integral membrane proteins (14, 15) (Figure 1B). The primary
components of tight junctions in the BBB are occludins, claudins,
junctional adhesion molecules (JAMS), zonula occludens (ZO)
proteins, and cytoplasmic accessory proteins (16, 17). Adherens
junctions, located in the paracellular space near the endothelial
cells’ basement membrane, significantly influence functional
tight junctions (Figure 1B). Both adherens junctions and tight
junctions are highly influenced by each other (12, 17–19). The
main component of adherens junctions is cadherins, which serve
the role of mediating cell-cell, homophilic adhesion between
adjacent endothelial cells (18–20). Together, these proteins
restrict the paracellular pathway into the CNS and impart the
high electrical resistance characteristic to the BBB (12, 21).
While the brain endothelial cells are integral to the creation of
a tight BBB, many other cells play active roles in the function of
the BBB (Figure 1A). The BBB contains a second basement
membrane, the parenchymal basement membrane, where
astrocytic end-feet tether (18). The astrocytic end-feet
surround 98% of the CNS microvasculature (22). Together
with the parenchymal basement membrane, astrocytes
compose the glial limitans, which block the passage of
leukocytes into the CNS, thus contributing to the immune
privilege of the CNS (18, 23). Additionally, pericytes play a
vital role in maintaining the BBB’s integrity. Pericytes block
larger molecules and ensure the astrocytic end-feet’s
polarization, regulating the astrocytic coupling to the BBB
(24, 25).
Macrophages associated with the BBB (termed border-
associated macrophages - BAMs) are found in the perivascular
Bodnar et al. CNS Barriers and TBI
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space and other barriers, including the blood-CSF barrier and the
meninges (26). These cells are critical in phagocytosis and innate
immune regulation and surveillance and have similar functions
to the microglia in the brain parenchyma (26).
Blood Brain Barrier Disruption After TBI
The cells of the BBB can withstand a certain amount of
mechanical strain. However, with TBI, this amount of tolerable
pressure is exceeded, resulting in the physical breaking of the
barrier (4). These mechanical changes result in bleeding,
shearing of tight junctions, and lesions to endothelial cells,
astrocytes, and pericytes following TBI (Figure 1C). Secondary
cascades continue for days-to-weeks after the injury, further
disrupting the BBB.
Evidence of bloody lesions in the brain on neuroimaging (CT
or MRI) is used clinically to assess the TBI severity. At all severity
levels of TBI, bleeds occur in animal models and human patients
(27), which may not be visible by routine clinical CT methods,
but can be seen by MRI and microscopically (Figure 1C). For
instance, small petechial hemorrhages have been found in both
children via T2 weighted MRI (28) and adults via susceptibility-
weighted MRI (29). In humans, these small microbleeds occur
throughout the brain after TBI but specifically accumulate at
the brain’s more physically vulnerable areas, such as the white/
gray matter interfaces (30). Microbleeds are a prevalent
pathology following mild (27%), moderate (47%), and severe
(58%) TBI via T2 weighted MRI (27). Evidence of microbleeds is
often the most prevalent pathology seen on imaging in human
fluid-attenuation inversion recovery (FLAIR) MRI and can
last up to 5 years after the initial injury, and those with
microbleeds were two times more likely to have a long-term
disability (31).
Junctional proteins get torn away from each other following
TBI (Figure 1C). Occludin, claudins, and ZO-1, and cadherins,
the major components of the BBB tight junctions, are reduced
after rodent blast injury (32), rodent and pig controlled cortical
impact (CCI) (33, 34), and cryogenic TBI (35). Shearing of tight
junctions and lesions to endothelial cells increases leakage of
blood serum proteins and other molecules across the BBB, as
recently reviewed (36). Tearing of junctional proteins leads to the
first phase of increased BBB permeability following TBI. When
exposed to blood-derived factors, the BBB cells, including
astrocytes and pericytes, become reactive. The second phase of
increased BBB permeability after TBI is the result of biochemical
changes as opposed to the physical disruption that dominates the
primary injury-induced BBB permeability (37). Increased
permeability of the BBB via these different mechanisms leads




FIGURE 1 | The Blood Brain Barrier (BBB). (A) Brain endothelial cells (BEC) form the first layer of the BBB. An endothelial basement membrane then surrounds the
BECs. Smooth muscle cells (SMC), pericytes, and border-associated macrophages (BAM) are in the next layer. Finally, the parenchymal basement membrane and
the astrocytic end-feet create the perivascular space. Interleukin-1 receptor 1 (IL-1R1) is expressed in the venous compartment of the BECs, presumably on both the
luminal and abluminal sides. (B) The junctions between endothelial cells form the major barrier component and consist of several proteins both in the intercellular
space and intracellular compartments. (C) Traumatic brain injury causes several alterations at the BBB. These changes include (1) loss of junctional proteins, (2)
microbleeds, (3) local and systemic increased cytokines, (4) pericyte disruption, (5) matrix metalloprotease (MMP) activation, (6) endothelial cell activation, (7)
leukocyte infiltration, and (8) astrocyte retraction from the barrier. Many of these changes have been linked either directly (solid arrow) or indirectly (dashed arrow)
with IL-1 signaling.
Bodnar et al. CNS Barriers and TBI
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When brain endothelial cells become reactive from the
primary and secondary injury (Figure 1C), there is increased
permeability, hypertrophy, and hemostatic pathway activation
(40). An example of alteration of brain endothelial cell function
is disrupted transport. Typically, this is a highly regulated
process. However, after TBI, there is an increase in
transendothelial vacuolar and vesicular transport and increased
pinocytotic activity (41). Lesions to brain endothelial cells
following experimental TBI to rodents also increase
permeability and further damage to the BBB. These changes
increase intracranial pressure and edema formation (42).
Pericytes are also damaged following TBI (Figure 1C). For
example, up to 40% of pericytes were found to be moved from
the blood vessels after a TBI, as a result of the primary insult and
secondary injury events (43). Further, TBI-induces
morphological changes to pericytes including degeneration,
necrosis, phagocytosis and hypertrophy (44, 45). This damage
in pericytes has functional consequences including alterations in
neurovascular coupling (46), which can lead to further
disruption of the BBB.
Gene expression changes in BBB cells include alterations to
various pathways that enhance inflammation, including major
histocompatibility (MHC) class I and II molecules, E-selectin,
VCAM-1 and ICAM-1 (40, 47). Also, matrix metalloproteinases
(MMPs) and vascular endothelial growth factor (VEGF) are
increased and linked to secondary barrier permeability after
TBI. VEGF is a trophic factor that leads to increased
angiogenesis (48), and increases blood vessels’ permeability as
part of its angiogenic properties. A TBI increases both VEGF and
its receptor (VEGFR) (49–51). VEGF causes phosphorylation of
endothelial proteins like ZO-1 and VE-cadherin, resulting in loss
of normal localization of these proteins (50). In microdialysate
from severe human TBI, MMP-1, -2, -3, and -9 were increased
(52). Similarly, TBI in rodents and cats increased MMP-2 and -9
(53–56). Microglia, astrocytes, pericytes and neurons can release
MMPs (57, 58). Changes in MMP activity can also be activated
by a loss of junctional proteins after experimental TBI (33).
MMPs, once activated, attack basal lamina proteins and degrade
tight junction proteins resulting in edema formation.
With the increased permeability of the BBB and the increased
expression of vascular adhesion molecules on brain endothelial
cells, there is increased leukocyte infiltration into the brain after a
TBI (Figure 1C). Within hours-to-days after injury, leukocytes
infiltrate into the brain by a process that requires interaction with
adhesion proteins in the brain endothelial cells (i.e., selectins)
and anchoring and docking proteins (i.e., ICAM-1) (50, 59).
After passing through the brain endothelial cell barrier, the
leukocytes must then pass the glial limitans. As the astrocytic
end-feet are retracted from the BBB, early following a TBI, the
leukocytes accumulate in the perivascular spaces (23), and tend
to congregate, especially around venules (60).
Once in the brain, leukocytes increase the inflammation and
further increase permeability, leading to edema (59, 61). For
example, neutrophils release MMP-9 to aid in the additional
recruitment of leukocytes into the brain (62), which further adds
to the BBB breakdown, exacerbating neuroinflammation,
neuronal degeneration, edema, and brain tissue damage (61).
Experimentally blocking the recruitment of neutrophils to the
injured brain reduced edema, tissue loss, apoptosis, and
microglia number after rodent TBI (59, 63). The damaged
caused by neutrophils – which peaks around 12-to-48 hours
after experimental TBI (64) – occurs via reactive oxygen species,
protease activation, elastase and MMP activation, and further
pro-inflammatory cytokine release (59). In addition, when
peripheral macrophages are blocked from entering the brain
through antagonism of CCR2 after TBI, there is a reduction in
the inflammatory profile as well as cognitive improvement (65).
On the other hand, leukocyte infiltration into the brain
parenchyma can be protective if disruption of the barriers
allowed pathogens to enter the brain, for instance (66).
While not extensively studied at the BBB following TBI,
border-associated macrophages are expected to become
reactive like other macrophages (67). In ischemic stroke,
border-associated macrophages increase vascular permeability,
increasing cells’ ability to infiltrate from the periphery, which is
correlated with reduced neurological function in stroke models
(67). In a middle cerebral artery occlusion model, increased
border-associated macrophages were seen in the perivascular
and subpial spaces as early as 16 hours after insult (67). Further,
these border-associated macrophages were characterized via
RNA sequencing and had increased chemokine production for
the recruitment of leukocytes across the BBB (67). As with other
disease mechanisms, there is potentially a similar mechanism
occurring following TBI, which has yet to be elucidated.
Mechanisms of IL-1 Signaling at the Blood
Brain Barrier After TBI
Two forms of IL-1 exist in the brain, IL-1a, and IL-1b. IL-1a is
expressed constitutively and is considered a damage-associated
molecular pattern. Microglia are the primary source of IL-1 (68),
although all CNS cells and cells throughout the body can make
IL-1. IL-1b is induced upon activation and then processed into
the active form via inflammasome and caspase-1 cleavage (69). A
truncated form of the IL-1 receptor, IL-1R3, is expressed
primarily in the brain (70), although much is unknown about
this receptor’s functions.
Following TBI, IL-1 is released early (hours-to-days), and can
remain chronically elevated over levels seen in uninjured tissue
(71, 72). Not only is IL-1 increased after TBI, but other molecules
involved in the activation of the IL-1b pathway, including
NLRP3, ASC, caspase-1, are also upregulated after TBI (73,
74). IL-1 is highly localized to the brain endothelium following
a TBI (75). The time-course of post-TBI neuroinflammation has
been heavily reviewed [see (5, 57, 76)], and it is not our goal here
to re-do these wonderful reviews. Instead, we would like to
demonstrate that IL-1 signaling is a common thread that can tie
changes to the different CNS barriers post-TBI (Figure 1C).
Leukocyte infiltration occurs mainly at the venous portion of
the cerebral vasculature (60), where IL-1R1 expression is highest
(Figures 2A, B). Leukocyte infiltration is a multi-step process,
including rolling, activation, adhesion, and transmigration (78).
IL-1 is responsible for activating endothelial cells as a part of the
Bodnar et al. CNS Barriers and TBI
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neuroinflammatory cascades resulting in increased expression of
many major proteins involved in leukocyte adhesion and
infiltration (79, 80). These IL-1 induced changes include
alterations to junctional proteins [e.g., occludin and ZO-1
(81)], increased expression of vascular adhesion molecules
[VCAM-1 and ICAM-1 via Nf-kB dependent mechanism (40,
79, 82)], and increase proinflammatory cytokines and
chemokines [e.g., G-CSF, IP-10 and CCL2 (40)]. Further,
pericytes can become activated by IL-1 signaling through IL-
1R1 (83); however, a link with this mechanism in TBI has not yet
been determined. IL-1R1 activation is thus sufficient for
leukocyte infiltration across the brain endothelium (7), and
leukocytes also release IL-1a and IL-1b (84), creating a
positive feedback loop.
While a direct connection with IL-1 and post-TBI
microbleeds has not been established, there is some correlative
evidence suggesting a role of IL-1 in microbleeds. IL-1 signaling
directly activates MMPs (85, 86). IL-1b and MMP-9 are
correlated with an increased risk for the rupture of aneurysms
(87) indicating a detrimental effect on the integrity of blood
vessels in the brain. Further, IL-1 signaling stimulates the release
of VEGF (23, 88), which increases CNS barriers permeability.
BLOOD-CEREBROSPINAL
FLUID BARRIER
As early as 300 B.C., Roman physician Herophilos described a
small structure of blood vessels found in the brain’s ventricles.
Now, over 2000 years later, this structure known as the choroid
plexus is still one of the most understudied structures in the CNS,
despite its many significant roles in CNS functioning (89, 90).
Namely, the choroid plexus is responsible for producing the
cerebrospinal fluid (CSF) and contains the blood-cerebrospinal
fluid barrier (89, 90). The blood-CSF barrier contains many
mechanisms that create a separation between the sensitive CNS
and the harsh peripheral environment.
Blood-CSF Barrier Overview
The blood-CSF barrier consists of a single-cell layer of cuboidal
epithelial cells that line and surround the highly vascular choroid
plexus (91) (Figure 3A). The choroid plexus is responsible for
producing CSF [for review, see (89, 90)]. The choroid plexus’s
epithelial cells are the principal constituents of the blood-CSF
barrier as well as the continuation of this barrier into the





FIGURE 2 | IL-1R1 gene expression in a naïve adult reporter mouse. (A) The IL-1R1 reporter mouse line expresses RFP via the IL-1R1 promoter (77) in discrete
tissue compartments as seen using RFP immunohistochemistry. (B) IL-1R1 expression is high in blood vessels within the brain parenchyma, (C) choroid plexus, and
(D) meninges. All of these areas are associated with one of the CNS barriers. (scale bar is 1mm in A, and 50 mm in B–D).
Bodnar et al. CNS Barriers and TBI
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and arachnoid villi of the meninges (12, 90, 92). The secretory
function of the epithelium is reflected in their structure, as these
cells have apical cilia that extend into the ventricles of the brain
and serve to increase the surface area for secretion and
monitoring of CSF composition (13, 91).
The choroid plexus capillary endothelial cells are uniquely
fenestrated; thus, they are “leaky” (89–91, 93) (Figure 3B). The
choroidal epithelial cells block paracellular diffusion of solutes
into the ventricles via tight junctions and adherens junctions
between cells (17). This serves to protect the CSF from changes in
the blood milieu and maintain homeostasis (17). The blood-CSF
barrier’s tight junctions contain the same families of proteins as
those in the BBB but are considerably more complex. The
proteins of the blood-CSF barrier tight junctions include
claudins-1, -2, -3, and -11, occludin, and JAMs-A and -C (17).
These proteins then bind to scaffolding proteins of the zona
occludens family to link the barrier to the actin cytoskeleton (17).
The adherens junctions of the blood-CSF barrier primarily
contain E-cadherin, a transmembrane protein that binds to
p120 and b-cantenin via its cytoplasmic tail (17). E-cadherin
contributes to the barrier’s dynamic nature, as it regulates
epithelial cell-cell contact and the plasticity of the junction (17).
While the tight junctions and adherens junctions tightly block
paracellular diffusion, the epithelial cells, much like the
endothelial cells of the BBB, have transporters that allow
nutrients and other select molecules to cross into the CSF as
well as to remove harmful substances (13, 19). The efflux of
lipophilic solutes out of the epithelial cells and ventricles occurs
via ABC family efflux pumps (18, 90). Conversely, a wide variety
of solute-specific transporters manage the influx to the ventricles
of ions and amino acids, as well as some other small
hydrophilic molecules (18, 90). Aquaporin-1 is also present
in the blood-CSF barrier and allows for the passive,
osmotically-driven influx of water into the ventricles for CSF
production (90).
The blood-CSF barrier draws similarities to the BBB in that it
has associated cells that serve many roles in the optimal
functioning of the barrier. In the blood-CSF barrier, these cells
are a type of immune cell known as the Kolmer (or epiplexus)
cells (91, 94). These choroid-associated macrophage-like cells
were first described in 1921 by Kolmer (93, 94). The Kolmer
cells attach to themicrovilli on the apical side of the epithelial cells





FIGURE 3 | The blood-CSF barrier. (A) The blood-CSF barrier surrounds the choroid plexus situated within the ventricles of the brain. (B) The blood-CSF barrier’s
endothelial cells are fenestrated, while the choroid plexus epithelial cells have tight junctions and adherens junctions between adjacent cells, creating a barrier.
Kolmer cells interact with the choroid plexus epithelial cells on the ventricle side. Interleukin-1 receptor 1 (IL-1R1) is located on epithelial cells. (C) Traumatic brain
injury causes alterations to the blood-CSF barrier, including (1) altered transporter localization and expression; (2) Kolmer cells become activated and retract their
processes; (3) local and systemic increased cytokines; (4) increased water permeability and edema; (5) loss of tight junctions; (6) matrix metalloprotease (MMP)
activity; and (7) increased leukocyte trafficking and activation. Many of these changes have been linked directly (solid arrow) or indirectly (dashed arrow) to IL-1 signaling.
Bodnar et al. CNS Barriers and TBI
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Blood-CSF Barrier Disruption After TBI
The choroid plexus is highly sensitive to physical force and
mechanical disruption caused by the primary injury after TBI
(96). The third ventricle is particularly sensitive to frontal blows,
while the lateral ventricles are more sensitive to lateral blows
(97). Mechanical disruption of the choroid plexus can
immediately alter fluid regulation in the brain resulting in
exasperation of edema.
Traumatic brain injury causes several alterations to the blood-
CSF barrier (Figure 3C). Damage to epithelial junctions can lead
to increased permeability leading to altered CSF composition
(97). Immediate loss of cilia on choroid plexus epithelial cells is
also seen after TBI (96), reducing the ability to secrete CSF. The
intracellular clefts in the blood-CSF barrier’s epithelial cell layer
undergo swelling, and the clefts widen following experimental
TBI (98, 99), increasing permeability through the blood-CSF
barrier. VEGF and MMPs (specifically MMP-9) increase
permeability and are elevated in the choroid plexus after CNS
trauma (50, 100). Changes to the blood-CSF barrier can explain
many TBI-induced metabolic changes. For example, a TBI
induces ionic balance disruption, as transporters such as the
Na-K-Cl transporter essential for restoring ion concentrations in
the CSF and interstitial fluid, are reduced by the loss of
ATP (101).
Intracranial pressure changes constitute a significant issue
following TBI, leading to irreversible damage to the brain tissue
(38). Edema results from increased fluid in the CNS parenchyma
and is both a result of decreased efflux of fluid and increased
influx (Figure 3C). The first phase of edema, termed vasogenic
edema is due to the increased permeability of cells at the BBB,
including endothelial cells and astrocytes (102–104). Vasogenic
edema, characterized by the swelling of cells typically associated
with the BBB, is also influenced by the blood-CSF barrier (101)
and increases intracranial pressure. Reduced aquaporin-4, a
water channel found on astrocytic end-feet, is linked with
vasogenic edema in animal models as early as 24 hours after
injury (105). The second phase of edema after TBI is cytotoxic
edema. This phase is attributed to cell swelling within the brain
parenchyma in the absence of BBB permeability changes (102–
104) and lasts much longer after TBI (59).
Inflammation in the choroid plexus more closely resembles
inflammatory processes in the periphery (93). Isolated choroid
plexus express different cytokines and chemokines, including
CXCL1, CXCL3, CCL2, LCN2, TNFa and IL-1b (57, 106, 107).
Kolmer cells, the associated macrophage-like cell in the blood-
CSF barrier, are altered after TBI, as seen by the appearance of
short, blunt, cytoplasmic processes and the increase in vesicles
(108) (Figure 3C). The reactive Kolmer cells appear to move
toward the blood-CSF barrier’s damage, similar to functions of
microglia and macrophages elsewhere in the brain (109).
Leukocyte transport from the periphery to the brain is also a
primary physiological function of the choroid plexus (110). The
choroid plexus expresses both P- and E-selectins, which are
required for T cell recruitment (107, 110). Increased movement
of leukocytes into the CSF has been found in experimental TBI
(50, 64) (Figure 3C). Once inside the CSF, these cells infiltrate
into the brain parenchyma. As with the BBB, most of the
leukocytes infiltrating via the blood-CSF barrier are
neutrophils (knowledge gained from multiple sclerosis models)
(96, 111). These neutrophils are found to be associated with the
choroid plexus and perivascular spaces.
Mechanisms of IL-1 Signaling at the
Blood-CSF Barrier After TBI
Most CNS studies of IL-1 signaling focus on the brain
parenchyma; yet, there are essential functions for IL-1 pathway
at the blood-CSF barrier (Figure 3C). IL-1 is released from
choroid plexus cells epithelium (93). Because of the fenestrations
within the capillaries in the blood-CSF barrier, this barrier is
more sensitive to changes in the periphery. Specifically, systemic
inflammation induces IL-1b expression in the choroid plexus
(112). Further, IL-1R1 expression is high in the choroid plexus
(113) (Figure 2C).
Brain injury in rodents results in increased IL-1b in the
choroid plexus (107). IL-1 signaling in the blood-CSF barrier is
correlated with increased permeability. Activation of enzymes,
like MMPs, increases permeability by a breakdown of basal
lamina and junctional proteins. Tissue inhibitors of
metalloproteinases (TIMPs) are also found in high
concentration in the choroid plexus (93), where IL-1 signaling
is high.
IL-1 increases chemokine release (114), responsible for the
infiltration of cells into the CSF and then subsequently moving
into the CNS parenchyma. While Kolmer cells could engage in
the trafficking of neutrophils (66), not much is known about the
involvement of IL-1 in Kolmer cells function and activation,
especially after TBI.
Loss of IL-1R1 in a hypoxia model reduced edema up to 90%
compared to wildtype animals (115). Neutralizing antibodies for
IL-1b delivered after TBI resulted in improved edema following
mouse CCI (116). Yet, conflicting evidence suggest that genetic
deletion of IL-1R1 was not successful at reducing brain edema
after CCI (75). A complete mechanism for how IL-1 may be
driving edema following TBI is not yet worked out, but likely
involves the choroid plexus and the blood-CSF barrier.
MENINGEAL BARRIER
The meninges are a grouping of different layers responsible for
protecting and separating the CNS from the skull and periphery.
There are three layers of meninges; dura mater, arachnoid mater,
and pia mater, from outermost to innermost (Figure 4). The
blood-CSF barrier is interconnected with the meningeal layer,
specifically the arachnoid layer. Under homeostatic conditions,
the meninges house many different local immune cell
populations such as macrophages, dendritic cells, innate
lymphoid cells, mast cells, neutrophils, B and T cells (117).
Each meningeal layer has a different cellular consistency,
density, and role in providing the CNS with a barrier between
the brain and skull.
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Meningeal Barrier Overview
The dura mater, the most superficial meninges layer, comprises
three layers: the periosteal, meningeal, and border cell layers
(Figure 4). The outermost layer, periosteal dura, lines the inside
of the skull and is composed of elongated fibroblasts (118, 119).
The middle layer, meningeal dura, is made offlattened, elongated
fibroblasts with small nuclei and dark cytoplasm (119). The
innermost layer, the dural border cellular layer, is typically
referred to as the subdural space or subdural compartment.
This layer is structurally weak because of the flattened
fibroblasts, which contain sinuous processes but lack collagen
and elastic fibers (120).
The arachnoid mater lies directly below the dura mater (119).
This meningeal layer is composed of two separate layers, each
with its own function: arachnoid barrier cellular layer and
arachnoid trabeculae (Figure 4). The arachnoid layer
constitutes the majority of the meninges’ barrier function as an
extension of the blood-CSF barrier. The many tight junctions
within the arachnoid barrier cellular layer help divide the CSF-
filled subarachnoid space from the fenestrated capillaries within
the dura (121). The un-innervated and avascular arachnoid
trabeculae consist primarily of connective tissue (119, 122).
The sub-arachnoid space – lying below the arachnoid barrier
cellular layer and within the arachnoid trabeculae – contains
arachnoid trabeculae cells, CSF, arteries and veins, and cranial
nerve roots (119).
The highly vascularized pia mater is tightly adhered to the
brain’s surface, contouring to the gyri and fissures, and forms the
leptomeninges with the arachnoid mater (Figure 4). The most
superficial pial layer is composed of flat overlapping mesothelial
cells, forming a tight connective layer, joined by desmosomes
and gap junctions, rendering this layer impermeable to CSF
along vessels within the perivascular space (121). Below this
cellular layer, the epipial layer consists primarily of collagenous
fibers, and the deeper intima pia is composed of reticular and
elastic fibers (121). On the surface of the brain parenchyma, the
glial limitans are formed by a dense network of astrocytic
processes covered by an outer basal lamina interconnected
with cells of the pia mater (123). Processes from surrounding
pial cells envelop small vessels that penetrate the neural surface
(119). These sheathed vessels create a perivascular space known
as Virchow-Robins spaces (121).
FIGURE 4 | The meningeal barrier. The meninges, covering the brain surface, consist of three main layers, the dura mater, the arachnoid mater, and the pia mater.
The dura mater consists of the periosteal, meningeal, and dural border cell layers. The arachnoid trabeculae imparts the majority of the barrier properties. The pia
mater covers the brain’s surface and connects with the astrocytic end-feet’s glial limitans. Interleukin-1 receptor 1 (IL-1R1) is located within the arachnoid and pia
mater. Traumatic brain injury tears the blood vessels running through and covered by the meninges, resulting in subdural hemorrhage (SDH) and subarachnoid
hemorrhage (SAH). Increased immune cell trafficking occurs through the altered meninges post-TBI. IL-1 signaling can be linked indirectly (dashed arrows) with
hemorrhage and leukocyte trafficking and activation.
Bodnar et al. CNS Barriers and TBI
Frontiers in Immunology | www.frontiersin.org May 2021 | Volume 12 | Article 6882548
Meningeal Barrier and TBI
Trauma, especially to frontal regions of the head, can lead to CSF
leakage, as dura adhered to the facial bones can be torn when
facial bones fracture (124). CSF leaks can heal on their own in
some cases. If left untreated, CSF leakages can lead to alterations
in intracranial pressure, development of bacterial meningitis, or
the formation of an intracranial abscess (124).
Vessels suspended in the meninges are particularly vulnerable
to the mechanical strain of TBI. Trauma often causes bleeding in
the vessels within and around the meninges. Blood pooled in the
subdural space, known as subdural hematoma (120), is seen in
10-20% of TBI patients and is prevalent in severe TBI (125, 126)
(Figure 4). Bleeding at the meningeal barrier following mild TBI
is not well studied. Subdural hematoma is associated with
increased mortality and poor outcomes (127). Chronic
subdural hematoma may enlarge and compress nearby
vasculature, causing increased intracranial pressure and
compress neurological structures. Traumatic subarachnoid
hematoma occurs when the mechanical force shear veins or
arteries within the meninges (128) (Figure 4). Traumatic
subarachnoid hematoma changes cerebral blood flow and
cerebral vessels (129). MRI findings, using contrast fluid-
attenuated inversion recovery (FLAIR), show that an increase
in meningeal bleeding is seen following TBI and can be a useful
diagnostic tool (128).
Following the initial impact and meningeal bleeding, a series
of clotting and inflammatory responses are initiated (120). Many
immune cells circulate through the meningeal barrier to act in a
surveillance capacity. CD4 positive T cells traffic through and
function to modulate the inflammatory make-up of the CSF,
which in turn can influence neuronal function (130). In response
to TBI, these T cells recognize danger-associated molecular
patterns (DAMPs) released from the brain into the CSF.
Damaged and necrotic cells caused by the initial trauma of TBI
release DAMPs (130). These can be various molecules including
IL-1a, IL-33, HMGB1, S100b, mitochondrial DNA, and ATP
among others and are sensed by pattern recognition receptors
(131). In CNS injury, this alarm signal induces chemokine
secretion, which recruits peripheral immune cells, like
monocytes and macrophage cells, into the brain via the
meningeal blood vasculature (132). Lacking either the alarm
signal (IL-33) or the chemokine receptor (CCR2) results in
reduced infiltration of peripheral immune cells following
neurotrauma (132).
Mechanisms of IL-1 Signaling at the
Meninges Post-TBI
Meninges are significantly enriched sources of IL-1b within the
CNS (112, 133). IL-1R1 is also expressed within the meninges
(113), and by the immune cells in the meninges (Figure 2D).
Thus, the meningeal barrier is an active zone for IL-1 signaling.
For instance, the presence of IL-1b in the meninges could cause
local T cell activation and expansion following a TBI (134, 135);
however, this remains to be experimentally defined. Indeed, there
are significant gaps in knowledge regarding the function of IL-1/
IL-1R1 in post-traumatic subdural or subarachnoid hematoma
(Figure 4).
In models of subdural hematoma, there are an increased
expression of inflammatory cytokines, neutrophil infiltration,
and VEGF (136, 137). These changes suggest a possible role
for IL-1/IL-1R1 in the secondary injury cascade of a subdural
hematoma. Increased levels of the IL-1 family of proteins occur
in people with subarachnoid hemorrhage and correlates with
poorer outcomes (138, 139). Therapeutic administration of
exogenous IL-1ra – to antagonize IL-1R1 – in patients with
subarachnoid hematoma, reduced inflammation markers (IL-6
and C-reactive protein), and improved Glasgow Outcome Scale
scores (140). More studies are needed to establish a causal role
for IL-1/IL-1R1 signaling in the pathophysiology of traumatic
subdural and subarachnoid hematomas.
BLOOD-RETINAL BARRIER
Characterized over 100 years ago by Schnaudigel, the blood-
retinal barrier provides an integral boundary between circulation
and the retina necessary to maintain a homeostatic environment.
The blood-retinal barrier is separated into an inner and outer
barrier, each with a distinct structure, leading to a complete
barrier (Figure 5A).
Blood-Retinal Barrier Overview
The inner blood-retinal barrier is located within the retinal
microvasculature and resembles the BBB (Figure 5B). It
contains tight junctions between retinal capillary endothelial
cells and is surrounded by pericytes, Müller cells, and astrocytes
(141). The Müller cell is responsible for forming and maintaining
the tight junctions between glia and endothelial cells (142, 143).
Astrocytes also provide various functions similar to the Müller
cell, such as structural support, forming and maintaining tight
junctions, and forming the blood-retinal barrier (144, 145).
Pericytes, located on the surface of retinal blood vessels, are
also critical in maintaining the blood-retinal barrier via
regulating blood flow and angiogenesis (146).
The outer blood-retinal barrier is comprised of tight junctions
between adjacent retinal pigment epithelium (147) and
resembles the structure of the blood-CSF barrier (Figure 5C).
The outer blood-retinal barrier separates the neural retina from a
network of vessels known as the choriocapillaris – the large blood
supplier for the neural retina (148). Tight junctions allow the
outer blood-retinal barrier to monitor and filter the influx of
solutes and nutrients from the choroid to the sub-retinal
space (147).
Paracellular transport across the blood-retinal barrier is
tightly regulated and is impermeable to larger molecules such
as glucose, amino acids, etc. (148, 149). However, the retina is
one of the most metabolically active tissues (150, 151). It contains
high concentrations of glucose transporters (152–154), and
lactate transporters (155–157). For a review of specific influx
and efflux transporter, see (158).
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Blood-Retinal Barrier and TBI
People often report increased sensitivity to light, retinopathy,
optic neuropathy, dysfunctional optic motility, and visual field
deficits following a TBI (159). Of the millions living with long-
term TBI-induced disabilities, 20-40% have visual issues (160),
and prevalence can be higher in specific populations, such as the
military (161).
While many TBI-induced visual deficits originate within the
brain stem and visual cortex, significant changes occur to the
visual system’s peripheral portions, including the blood-retinal
barrier (162). The retinal ganglion cells – responsible for
sensation of light and the formation of the optic nerve – are
linked to common post-TBI symptoms including dry eye,
headache, and sleep issues (163). TBI causes cell death and
thinning of the retinal ganglion cell layer, including apoptosis
of the retinal ganglion cells (160, 164, 165). Retinal ganglion cells
are susceptible to reactive oxygen species, such as that found in
the retina after a CCI in mice (160) (Figure 5B).
Macular edema, which involves fluid accumulation within the
retinal layers that causes reduced blood flow and visual
impairments, is often seen following trauma (149). Multiple
cell types are responsible for the increased blood-retinal barrier
permeability and fluid disruptions. Müller cells release MMPs,
breaking down tight junctions within the inner and outer
barriers (149), however a connection with TBI has not yet
been discovered. Leukocytes, adhered to retinal vessels,
produce nitric oxide and other pro-inflammatory mediators,
increasing the blood-retinal barrier’s leakiness after a TBI (149)
(Figure 5B). Retinal pericytes’ function post-TBI remains
undefined. Pericytes changes, such as in diabetic retinopathy,
can alter vascular tone, and cause edema and ischemia (149, 166).
Mechanisms of IL-1 Signaling at the
Blood-Retinal Barrier Post-TBI
IL-1b is increased in the optic nerve (167), and blood-retinal
barrier (168) and IL-1R1 is increased in the retina (169) in
experimental models of TBI. The exact source of IL-1 in the
retina has not been worked out. The IL-1 could signal via the
blood-retinal barrier’s endothelial cells that express IL-1R1 (169).
Retinal pigment epithelium exposed to IL-1b, in vitro, reduces
claudin-1, ZO-1, and occludin (170, 171). In vitro, retinal
pericytes release inflammatory mediators (such as, IL-8, CCL2
and CCL5), and increase expression of adhesion molecules (such
as, ICAM-1 and VCAM-1), following IL-1b stimulation (172). In
vivo, direct stimulation with IL-1b causes increased leakiness of
the endothelial cell barrier (173). Thus, IL-1 could potentially be
a mechanism for increased permeability and leukocyte trafficking
at the blood-retinal barrier after TBI; however, experimental
confirmation in TBI models is lacking (Figures 5B, C).
BARRIER OF THE LESION CORE
Astrocytes and meningeal fibroblasts form the lesion barrier or
‘scar’ after a TBI (174, 175). The astrocytic barrier closes the
wound and restricts leukocyte trafficking, protecting the
remaining neurons (23). Extracellular matrix proteins like




FIGURE 5 | The blood-retina barrier. (A) The blood-retina barrier consists of two separate layers. The first (outer) around the choriocapillaris blood vessels, and the
second (inner) around the blood vessels in the retinal ganglia cell layer. (B) The inner barrier consists of endothelial cells surrounded by pericytes, astrocytic end-feet,
and specialized glial cells called Müller cells. Here, a TBI increases permeability and results in edema and increased leukocyte infiltration. Müller cells pull away from
the barrier and activate to release reactive oxygen species (ROS) and cytokines. (C) The retinal pigment epithelial cells (RPE) connected via tight junctions form the
outside barrier with the choriocapillaris blood vessels. Here, a TBI causes increased fluid accumulation through disrupted tight junctions resulting in edema. Most
connection with IL-1 signaling is indirect (dashed arrows), while some direct (solid arrow) evidence connects IL-1 signaling with leukocyte trafficking.
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further deposited in the lesion barrier (175). Leukocytes infiltrate
within the fibrotic scar and contribute to debris clearance and
inflammation (175). While thought to be primarily protective,
the lesion barrier’s scar is also associated with increased
inflammation, neuronal damage, post-traumatic epilepsy, BBB
disruption, and tissue damage (176, 177).
Mechanisms of IL-1 Signaling at the
Lesion Core After TBI
The astrogliosis required for the formation of the astrocyte scar
at the lesion following TBI can be directly activated via IL-1
released mainly through microglia. In mice lacking IL-1R1,
GFAP immunoreactivity was delayed following a penetrating
TBI model (178). In vitro, astrocytes exposed to IL-1b increase
levels of GFAP, a characteristic response of astrogliosis (179). In
vitro, IL-1 exposure increases fibroblast production of
extracellular matrix proteins (180, 181). More work is
warranted to directly test astrocyte and fibroblast IL-1
signaling in scar formation after TBI.
CONCLUSION
TBI causes a plethora of pathologies to the CNS barriers, including
but not limited to the BBB. Each CNS barrier is unique, yet most
mechanistic understanding of the TBI-induced barrier
pathophysiology is limited to the BBB. Common among all the
barriers are increased inflammatory reactions and increased
immune cell trafficking from the periphery into the CNS. CNS
barriers express IL-1R1 (Figure 2), and IL-1 signaling induces
leukocyte infiltration (7, 182, 183) and many other inflammatory-
associated barrier changes. IL-1 is associated with worse outcomes
in patients with TBI (74, 184). Further, IL-1 is associated with an
increased risk for developing post-traumatic epilepsy (185, 186), and
blocking IL-1 signaling reduces lesion size, neurodegeneration, and
improves behavior (187–189). For review of IL-1 therapies see
(190, 191).
Many of the current connections between IL-1 signaling post-
TBI are correlative. The BBB and blood-CSF barrier provides the
most comprehensive of the TBI and IL-1 interactions. However,
a direct connection between IL-1 signaling and several post-
traumatic barrier pathologies, including microbleeds, pericyte
disruption, loss of junctional proteins, Kolmer cells at the blood-
CSF barrier, all require further investigation. The meningeal
barrier and the blood-retinal barrier present the most
opportunity for further exploration in the TBI field as there is
no knowledge of IL-1’s function in these barriers. Most work at
the CNS barriers has focused on IL-1b; thus, some assumptions
remain regarding the function of IL-1a at the CNS barriers.
Future research is needed to determine differential effects of IL-
1a and IL-1b at the CNS barriers, as IL-1a and IL-1b can cause
differing responses (192, 193). As scientific tools become more
advanced, the understanding of IL-1’s role in TBI-induced
barrier dysfunction will improve, as IL-1 is an attractive target
for CNS barrier targeted interventions.
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